Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $36.89 USD
Change Today +1.61 / 4.56%
Volume 378.0K
TTPH On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

tetraphase pharmaceuticals i (TTPH) Snapshot

Open
$35.50
Previous Close
$35.28
Day High
$37.12
Day Low
$35.44
52 Week High
01/9/15 - $44.55
52 Week Low
05/15/14 - $8.35
Market Cap
1.3B
Average Volume 10 Days
402.3K
EPS TTM
$-2.48
Shares Outstanding
36.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TETRAPHASE PHARMACEUTICALS I (TTPH)

tetraphase pharmaceuticals i (TTPH) Related Bloomberg News

View More Bloomberg News

tetraphase pharmaceuticals i (TTPH) Related Businessweek News

No Related Businessweek News Found

tetraphase pharmaceuticals i (TTPH) Details

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multi-drug resistant infections. Its lead product candidate includes eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant Gram-negative infections. The company is conducting a Phase 3 clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and a second Phase 3 clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy. It is also developing TP-271, a preclinical compound for respiratory diseases caused by bacterial biothreat pathogens; and TP-6076, a preclinical Gram-negative program for multidrug-resistant Gram-negative infections. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.

55 Employees
Last Reported Date: 03/6/15
Founded in 2006

tetraphase pharmaceuticals i (TTPH) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $420.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $318.0K
Chief Medical Officer
Total Annual Compensation: $360.0K
Compensation as of Fiscal Year 2014.

tetraphase pharmaceuticals i (TTPH) Key Developments

Tetraphase Pharmaceuticals, Inc. Announces Detailed Results from Phase 3 Clinical Trials of Eravacycline

Tetraphase Pharmaceuticals, Inc. announced the first detailed results from phase 3 clinical trials of its lead drug candidate, eravacycline, in development to treat complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI). These results are being presented at the 25thEuropean Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place on April 25 to 28 in Copenhagen, Denmark. In IGNITE1, eravacycline met the primary endpoint of statistical non-inferiority of clinical response at the test-of-cure (TOC) visit. The primary analysis under the U.S. Food and Drug Administration (FDA) guidance was conducted using a 10% non-inferiority margin in the microbiological intent-to-treat (micro-ITT) population (n=446). Under the European Medicines Agency (EMA) guidance, the primary analysis was conducted using a 12.5% non-inferiority margin of the clinically evaluable (CE) patient population (n=477). In the micro-ITT population, 86.8% of patients receiving eravacycline achieved a clinical cure compared to 87.6% of patients receiving ertapenem. The lower and upper bounds of the 95% confidence interval were -7.1% and 5.5%, respectively. In the CE population, 92.9% of patients receiving eravacycline achieved a clinical cure compared to 94.5% of patients receiving ertapenem. The lower and upper bounds of the 99% confidence interval were -7.9% and 4.4%, respectively. The most common Gram-negative pathogens in the study included Escherichia coli, Klebsiella pneumonia and Pseudomonas. Eravacycline achieved high cure rates against these pathogens, as well as in patients with Acinetobacter baumannii and in patients with suspected ESBL-producing pathogen isolates. In the lead-in portion of IGNITE2, both IV-to-oral dosing regimens of eravacycline (1.5 mg/kg IV followed by 200 mg or 250 mg) compared favorably to levofloxacin for the treatment of cUTI, supporting the advancement of the trial into its pivotal portion. Efficacy outcomes were microbiological success and responder rates (defined as subjects with both clinical cure and successful microbiological outcome) in all randomized subjects (n=143) with a baseline pathogen identified (micro-ITT population, n=75) and the microbiologically evaluable (ME) population (n=62) at a post-treatment visit 7 days after the last dose of study drug. Patient demographics were well matched across all treatment groups. In the micro-ITT population, the responder outcome, which was the primary endpoint for the FDA, for the IV-to-oral 200 mg (n=24), IV-to-oral 250 mg (n=28) and levofloxacin groups (n=23) were 70.8%, 64.3% and 52.2%, respectively. Microbiological response was 75.0%, 64.3% and 56.5%, respectively. In the ME population, the microbiological response, which was a primary endpoint for the EMA, were 83.3% (n=18), 78.2% (n=23) and 61.9% (n=21), respectively. The pharmacokinetics for both oral doses of eravacycline were comparable to the IV formulation. The spectrum of pathogens in this trial was similar to that seen in other pivotal trials in this patient population. The most common Gram-negative pathogens in the study included Escherichia coli, Klebsiella pneumoniae, and Enterococci. Responder rates for levofloxacin resistant isolates (n=24) were 83.3% for eravacycline IV-to-oral 200 mg, 72.7% for eravacycline IV-to-oral 250 mg and 42.9% for levofloxacin.

Tetraphase Pharmaceuticals, Inc. Announces Executive Changes

Tetraphase Pharmaceuticals, Inc. announced the appointment of Gerri Henwood, President and Chief Executive Officer of Recro Pharma, to the company's Board of Directors. Ms. Henwood brings more than 30 years' experience in product commercialization, clinical development and regulatory approval processes to the Board. She replaces Steven Gullans, co-founder and partner of Excel Venture Fund. Ms. Henwood currently serves as President and Chief Executive Officer and Director of Recro Pharma. Ms. Henwood currently serves on the board of two private companies and was previously a member of the board of directors of MAP Pharmaceuticals, Inc. and Alkermes plc.

Tetraphase Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 08:40 AM

Tetraphase Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 08:40 AM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Guy MacDonald, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TTPH:US $36.89 USD +1.61

TTPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TTPH.
View Industry Companies
 

Industry Analysis

TTPH

Industry Average

Valuation TTPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 120.2x
Price/Book 10.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 132.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TETRAPHASE PHARMACEUTICALS I, please visit www.tphase.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.